Executives On The Move: Three CEOs, Four CMOs And Five CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at AdvanCell, MitoRx Therapeutics and Ambros Therapeutics, internal moves at Bayer, plus Soley Therapeutics gets a new CBO from Eli Lilly.
Scrip - June 18, 2026

Oryzon On The Up As AML Drug Nears Phase III
The Spanish biotech’s LSD1 inhibitors are advancing in both oncology and CNS.
Scrip - June 18, 2026

F2G, Shionogi Report Positive Phase III Results For Antifungal Olorofim In Invasive Aspergillosis
The companies have delivered positive late-stage data for investigational antifungal olorofim, marking a key development in the program's trajectory.
Scrip - June 18, 2026

Clue-SDK Deal Opens A Parallel Route For Femtech Into Insured Care, Bypassing Germany’s DiGA
German private insurer SDK is funding access to Clue's period-tracking app for its members, a move Clue calls a world first. The deal sidesteps Germany's DiGA reimbursement framework, hinting at a parallel route for femtech into insured benefits.
Medtech Insight - June 18, 2026

The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin
Generics Bulletin senior reporter Urt? Fultinavi?i?t? talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity.
Generics Bulletin - June 18, 2026

Dr Reddy’s Challenges Bosulif With 180-Day Lead
Through a partnership with MSN Laboratories, Dr Reddy’s has launched the first US generic version of Bosulif (bosutinib) 400mg tablets with 180-day exclusivity.
Generics Bulletin - June 18, 2026

Sumatriptan Surge Drives UK Price Rises In May
Generic sumatriptan 50mg and 100mg tablets saw their average UK trade prices increase by more than five times in May, leading a raft of triple-digit rises that also included multiple presentations of digoxin.
Generics Bulletin - June 18, 2026

FDA Review Revives Outlook’s Long-Delayed Bevacizumab Hopes
Outlook Therapeutics is nearing a pivotal FDA decision on Lytenava, raising hopes that the US could soon get its first approved ophthalmic bevacizumab for wet AMD after years of regulatory setbacks.
Generics Bulletin - June 18, 2026

Italian Strikes Cloud Teva’s TAPI Divestment Plans
Teva’s TAPI restructuring is drawing labor opposition in Italy as its Villanterio site faces potential closure, while around 250 roles are set to go in Israel, as the API unit remains marked for eventual divestment.
Generics Bulletin - June 18, 2026

Biogen Buys RayThera, The Third Exit For Its Serial Founders
The founders of RayThera complete a hat-trick as Biogen snaps up the immunology-focused biotech for up to $1bn.
Scrip - June 18, 2026

‘No Compromise’: How Opella Is Tackling The Hardest Parts Of Sustainability
Opella's chief manufacturing and supply officer, Rafik Amrane, talks to HBW Insight about the company's commitment to sustainability, emphasizing "there’s absolutely no compromise on what we do.”
HBW Insight - June 18, 2026

GLP-1s, Insulins Reshaping China’s Drug Exports, Thanks To MNCs
As multinationals switched to partly supplying global markets from manufacturing facilities in China, the country’s exports of GLP-1 and insulin analog preparations surged in 2025 and well into 2026.
Scrip - June 18, 2026

Deals In Depth: May 2026
Seven $1bn+ alliances were penned in May, and three exceeded $2bn (two of those werein excess of 11 figures). In the top alliance by deal value, Hengrui Pharma?and?Bristol Myers Squibb entered into a potential $15.2bn global collaboration to advance a portfolio of 13 early-stage programs.
In Vivo - June 18, 2026

US Supplement Industry Questions Sources For Texas AG’s ‘Harmful Ingredients’ Investigation
“Far too many corporations have snuck harmful ingredients in their products,” says Texas AG and GOP Senate nominee Ken Paxton. “The importance of grounding regulatory action in sound science is illustrated by a cautionary precedent,” cautions NPA.
HBW Insight - June 18, 2026